Bhuvana Sagar, MD: At Cigna, we do have a care coordination model with a patient-centered medical home in place. We do incentivize providers for their adherence to NCCN guidelines, and that is something that we continue to look at to see how we can broaden the scope of it. We’re also looking to see an implementation of pathways in the future, to see if that would add value as well—and how to incentivize them.
Ideally (in lung cancer, for example), it would be great if you can incentivize providers. If they have a patient who has adenocarcinoma, and they’re running mutation studies and treating the patient appropriately based on a mutation study—let’s say the patient has a PD-1 (programmed death-1) status greater than 50% in the first-line setting and they are offered KEYTRUDA [pembrolizumab]. So, the best-case scenario would be to benchmark all of this and understand which providers are following the guidelines and, then, incentivize them. We’re not there yet (at this point), but we are continuing to look at different ways of incentivizing providers to encourage quality care and improve outcomes.
We have not isolated lung cancer in and of itself. It is one of the top 3 cancers in a lot of our population. Overall, it’s either breast, lung, or colon cancer in our demographic population. They get incorporated with the general cancer category and looked at as a broader group (rather than specifically as lung cancer subsets). But what do I think would be good quality measures for lung cancer patients? Ideally, it would be adherence to NCCN guidelines. Are they evaluating the patient’s performance status? Is pain management being done appropriately? Which treatments, ideally, are offering the best chance for overall survival rather than progression-free survival? I think overall survival may be an easier data point to collect than progression-free survival. Those are things that I think would add value, in general. I don’t think, at this point, there are a lot of downsides for us providers, just yet, in terms of overall cost of care. In the near future, when it does happen, providers need to be able to assess their patients and educate their patients before they start patients on therapy.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More